Profluent

What

Profluent is an AI-driven protein design company focused on creating new proteins for use in medicine, agriculture, and other biological applications. Its platform is positioned around “authoring” biology with AI, including proteins inspired by natural scaffolds and proteins designed from scratch.

The company appears to serve biotechnology, life sciences, and research-oriented partners that need novel biological tools or engineered proteins. Based on the page, the core workflow is using machine learning and biology expertise to design proteins for specific functions, with OpenCRISPR presented as a flagship example of an AI-designed gene editor.

Features

• AI-based protein design — Profluent uses AI to write proteins, which can help teams explore new biological designs beyond traditional discovery methods.
• Natural-scaffold and de novo design approaches — The platform supports proteins derived from existing biological patterns as well as designs created from scratch, giving flexibility in how candidates are generated.
• OpenCRISPR gene editor development — The company highlights OpenCRISPR as the first AI-designed gene editor, showing a concrete application of its design approach in gene editing.
• Cross-industry application focus — Profluent positions its protein design work for therapeutics, industrial enzymes, agriculture, and related fields, suggesting broad applicability of the underlying platform.
• Partnership-oriented model — The site emphasizes partnerships, indicating that Profluent likely works with external organizations to apply its protein design capabilities to specific innovation programs.
• Interdisciplinary team foundation — The company combines machine learning and biology expertise, which is important for translating generative models into practical protein design efforts.

Helpful Tips

• Validate where the platform ends and services begin — The page presents strong technical positioning, but it does not clearly separate self-serve software, collaborative research, and partnership delivery models.
• Ask for evidence on downstream performance — For protein design platforms, the key evaluation criteria are usually experimental validation, function, safety, and manufacturability, none of which are detailed here.
• Clarify the development stage by application area — Gene editing, therapeutics, and industrial enzymes have very different requirements, so buyers should confirm which use cases are exploratory versus mature.
• Review partnership structure early — Since partnerships are a prominent part of the site, teams should understand IP ownership, design responsibilities, and experimental validation roles before engaging.
• Assess model-to-lab workflow — The page describes AI authorship, but it does not explain screening, iteration, or wet-lab integration, which are critical for practical adoption in this category.